Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2018 | Factors determining the effectiveness of treatment with ATG following transplantation

Jaap Jan Boelens • 18 Mar 2018
EBMT 2018
General Anti-thymocyte globulin Antibodies

Anti-thymocyte globulin (ATG) is immunosuppressive antibody that has been around for over 30 years, which is used to prevent graft-versus-host disease (GvHD) and the rejection of transplanted tissue. In this interview, Jaap Jan Boelens, MD, PhD, from UMC Utrecht, Utrecht, Netherlands, speaks about the results of his study investigating the pharmacokinetic profile of ATG in 500 cancer patients that received stem cell transplantation. This video was recorded at the 2018 European Group for Blood and Marrow Transplantation (EBMT) Annual Meeting, held in Lisbon, Portugal.

More from Jaap Jan Boelens

4:54
Predicting immune reconstitution following alloHSCT
Jaap Jan Boelens • 24 Apr 2022
3:20
Second cord blood transplant for patients who relapse following alloHSCT
Jaap Jan Boelens • 24 Apr 2022
4:53
The influence of the pulmonary microbiome on outcomes after alloHSCT
Jaap Jan Boelens • 24 Apr 2022
3:23
PARACHUTE trial: ATG in HCST
Jaap Jan Boelens • 1 Sep 2020

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals